Pioneering prostate biopsy device showcased at MEDICA 2021 -- MEDICA - World Forum for Medicine


ABHI Association of British Healthcare Industries Ltd.

Pioneering prostate biopsy device showcased at MEDICA 2021

UK manufacturer JEB Technologies Ltd, a specialist product development company for the medical device industry, will be joining the ABHI UK Pavilion at MEDICA 2021 on the (15 – 18 November 2021) to  introduce  a novel device designed to facilitate  the taking of prostate biopsies.  

The CamPROBE device (Cambridge Prostate Biopsy Device) aims to provide a simple and low-cost alternative to the current  methods for acquiring prostate tissue to confirm or exclude a diagnosis prostate cancer.   The device is intended to facilitate transperineal prostate biopsies under local anaesthetic.

The transrectal biopsy route (the current most common method for prostate biopsies) can carry a significant risk of infections and severe sepsis as during the transrectal approach the needle has to traverses the bowel a number of times on the way to the prostate.

CamPROBE ,however, facilitates  biopsies through the more sterile perineal skin (transperineal) under the gentials using simultaneous local anaesthetic delivery through an integrated needle. system It is an alternative to transrectal and other current transperineal devices and only needs two body entry puncture points, resulting in low pain scores, enhanced patient comfort and patient acceptability, Initial indications are that  cancer detection ability is equivalent to other biopsy methods based on a multicenter clinical trial. Access through the perineum virtually eliminates the risks of infection and sepsis, compared to transrectal procedures.

JEB Technologies  said: “We are delighted to be joining the ABHI UK Pavilion at MEDICA this year, where we will be  introducing  a disruptive technology to facilitate easier uptake of the  transperineal route for prostate biopsies. We have developed the CamPROBE in conjunction with the University  of Cambridge and Cambridge University Hospitals in the UK.

We are planning further clinical trials and post market activities that we hope will prove that  CamPROBE is the optimum device for  safer, low-cost prostate biopsies that eliminates infections and sepsis risks and is ideally suited for the local  anaesthetic  outpatient setting.

Our aim is to make the lives of patients better through a more simple and less painful way of undertaking this very common procedure and hopefully benefit the millions of men who have prostate biopsies every year. We look forward to meeting new partners at the event.”


The CamPROBE device (Cambridge Prostate Biopsy Device) is a surgically invasive, transient, single use, sterile device consisting of a stainless steel cannula and an integrated coaxial needle.


The CamPROBE is inserted at 2 points on either side of the perineum mid-line.  It is then advanced to the prostate with simultaneous targeted local anaesthetic infiltration to deeper structures (including pelvic muscles) using the integrated delivery needle and under transrectal ultrasound guidance. Once in position, the delivery needle is removed and the CamPROBE cannula can be used as an access sheath for prostate biopsies. The CamPROBE can be angled or re-positioned to reach different areas without superficial or deep structure re-puncture.

With over 2 million biopsies occurring each year in Europe and North America[1], the device intends to revolutionise current practice.

Paul Benton, Managing Director, International at the ABHI added: “Prostate cancer is the most common cancer among men, but it can often be treated successfully, especially when detected early. It is a really promising technology, and we are delighted to be supporting JEB Technologies in introducing it at MEDICA.”

MEDICA is taking place from 15 – 18 November 2021 and throughout the show, JEB Technologies Ltd will be located on the ABHI UK Pavilion – hall 16  J42 . For more information, visit

[1] Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353–65.

Exhibitor Data Sheet